Seeking Alpha

AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care

VALENCIA, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound ...
Nasdaq

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
Morningstar

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm ®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and ...
Morningstar

Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System

VALENCIA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today reaffirmed ...
Yahoo Finance

CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds

VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical ®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today announced ...
Business Wire

RECELL® Study in Facial Burns Shows Excellent Cosmetic Outcomes

The study suggests that a dermal matrix combined with RECELL could be used as a one-stage procedure in the management of full-thickness burns. “ We are pleased to see researchers evaluate additional ...
Benzinga.com

Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals

On Tuesday, Avita Medical, Inc. (NASDAQ:RCEL) revised its revenue guidance for the fourth quarter and full year of 2024. The regenerative medicine company adjusted its projections due to ...
Seeking Alpha

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns Burns and full-thickness ...
The Globe and Mail

Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System

Analysis of U.S. national burn registry data demonstrates 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL versus traditional skin grafting More than $42,000 per ...
The Globe and Mail

CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds

Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases ...
Enid News & Eagle

AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, ...